PharmaCyte Biotech Inc Net Assets
PharmaCyte Biotech Inc net assets. Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) has net assets worth $34.98 Million USD as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($46.75 Million) and total liabilities ($11.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PMCB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $34.98 Million |
| % of Total Assets | 74.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | -61.1% |
| 10-Year Change | 332.54% |
| Growth Volatility | 309.36 |
Net Assets of PharmaCyte Biotech Inc (2004–2026)
Net assets of PharmaCyte Biotech Inc from 2004 to 2026. This chart illustrates how PharmaCyte Biotech Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of PharmaCyte Biotech Inc to measure how much of total assets are equity-financed.
Annual Net Assets for PharmaCyte Biotech Inc (2004–2026)
The table below shows the annual net assets of PharmaCyte Biotech Inc from 2004 to 2026. For live market cap and overall valuation, see PharmaCyte Biotech Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | $34.98 Million | -32.59% |
| 2025-04-30 | $51.89 Million | +31.32% |
| 2024-04-30 | $39.51 Million | -45.64% |
| 2023-04-30 | $72.69 Million | -19.16% |
| 2022-04-30 | $89.92 Million | +1246.21% |
| 2021-04-30 | $6.68 Million | +31.25% |
| 2020-04-30 | $5.09 Million | +0.98% |
| 2019-04-30 | $5.04 Million | -12.64% |
| 2018-04-30 | $5.77 Million | -28.67% |
| 2017-04-30 | $8.09 Million | +23.99% |
| 2016-04-30 | $6.52 Million | +9.88% |
| 2015-04-30 | $5.94 Million | -33.62% |
| 2014-04-30 | $8.94 Million | +1070.46% |
| 2013-04-30 | $-921.46K | +45.79% |
| 2012-04-30 | $-1.70 Million | +37.72% |
| 2011-04-30 | $-2.73 Million | -39.88% |
| 2010-04-30 | $-1.95 Million | -162.47% |
| 2009-04-30 | $3.12 Million | -57.99% |
| 2008-04-30 | $7.44 Million | +73.48% |
| 2007-04-30 | $4.29 Million | -2.85% |
| 2006-04-30 | $4.41 Million | +440.66% |
| 2005-04-30 | $-1.30 Million | -744.12% |
| 2004-04-30 | $-153.43K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaCyte Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10378009300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
PharmaCyte Biotech Inc Net Assets Breakdown (April 2026)
PharmaCyte Biotech Inc net assets breakdown by equity component as of April 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.60K | 0.01% |
| Other Comprehensive Income | $-20.80K | -0.06% |
| Other Components | $137.71 Million | 413.60% |
| Total Equity | $33.29 Million | 100.00% |
PharmaCyte Biotech Inc Competitors by Market Cap
The table below lists competitors of PharmaCyte Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ranplan Group
ST:RPLAN
|
$3.65 Million |
|
Arcadia Minerals Ltd
AU:AM7
|
$3.65 Million |
|
ZhongDe Waste Technology AG
F:ZEF
|
$3.65 Million |
|
Highway Holdings Limited
NASDAQ:HIHO
|
$3.65 Million |
|
Burley Minerals Ltd
AU:BUR
|
$3.65 Million |
|
Indus Gas Ltd
F:59Q
|
$3.64 Million |
|
Yu Group PLC
LSE:YU
|
$3.64 Million |
|
APC Minerals Ltd
AU:APC
|
$3.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaCyte Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 51,891,069 to 33,294,926, a change of -18,596,143 (-35.8%).
- Net loss of 19,424,654 reduced equity.
- Dividend payments of 246,005 reduced retained earnings.
- Share repurchases of 401,625 reduced equity.
- New share issuances of 6,182,447 increased equity.
- Other comprehensive income increased equity by 3,073.
- Other factors decreased equity by 4,709,379.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.42 Million | -58.34% |
| Dividends Paid | $246.00K | -0.74% |
| Share Repurchases | $401.62K | -1.21% |
| Share Issuances | $6.18 Million | +18.57% |
| Other Comprehensive Income | $3.07K | +0.01% |
| Other Changes | $-4.71 Million | -14.14% |
| Total Change | $- | -35.84% |
Book Value vs Market Value Analysis
This analysis compares PharmaCyte Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-04-30 | $-0.13 | $0.34 | x |
| 2003-04-30 | $-0.04 | $0.34 | x |
| 2004-04-30 | $-2.44 | $0.34 | x |
| 2005-04-30 | $-18.70 | $0.34 | x |
| 2006-04-30 | $48.40 | $0.34 | x |
| 2007-04-30 | $39.56 | $0.34 | x |
| 2008-04-30 | $66.39 | $0.34 | x |
| 2009-04-30 | $20.55 | $0.34 | x |
| 2010-04-30 | $-8.33 | $0.34 | x |
| 2011-04-30 | $-11.68 | $0.34 | x |
| 2012-04-30 | $-6.80 | $0.34 | x |
| 2013-04-30 | $-3.13 | $0.34 | x |
| 2014-04-30 | $23.00 | $0.34 | x |
| 2015-04-30 | $12.64 | $0.34 | x |
| 2016-04-30 | $13.00 | $0.34 | x |
| 2017-04-30 | $14.35 | $0.34 | x |
| 2018-04-30 | $0.01 | $0.34 | x |
| 2019-04-30 | $0.00 | $0.34 | x |
| 2020-04-30 | $0.00 | $0.34 | x |
| 2021-04-30 | $0.00 | $0.34 | x |
| 2022-04-30 | $5.79 | $0.34 | x |
| 2023-04-30 | $3.73 | $0.34 | x |
| 2024-04-30 | $4.12 | $0.34 | x |
| 2025-04-30 | $7.08 | $0.34 | x |
| 2026-04-30 | $3.97 | $0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaCyte Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-58.34%) is above the historical average (-61.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.06K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.88K |
| 2004 | 0.00% | -72375.79% | 0.01x | 0.00x | $-1.71 Million |
| 2005 | 0.00% | -4951.60% | 0.26x | 0.00x | $-4.15 Million |
| 2006 | -212.73% | -1747.61% | 0.10x | 1.16x | $-9.83 Million |
| 2007 | -84.32% | -309.00% | 0.27x | 1.03x | $-4.04 Million |
| 2008 | -51.00% | -318.66% | 0.16x | 1.02x | $-4.54 Million |
| 2009 | -225.48% | -1078.31% | 0.11x | 1.93x | $-7.36 Million |
| 2010 | 0.00% | -2278.89% | 0.22x | 0.00x | $-5.80 Million |
| 2011 | 0.00% | -1109.32% | 0.10x | 0.00x | $-1.12 Million |
| 2012 | 0.00% | -2853.62% | 0.03x | 0.00x | $-1.73 Million |
| 2013 | 0.00% | -13142.29% | 0.00x | 0.00x | $-1.51 Million |
| 2014 | -304.77% | 0.00% | 0.00x | 1.04x | $-28.15 Million |
| 2015 | -182.87% | 0.00% | 0.00x | 1.34x | $-11.45 Million |
| 2016 | -92.96% | 0.00% | 0.00x | 1.10x | $-6.72 Million |
| 2017 | -54.95% | 0.00% | 0.00x | 1.07x | $-5.25 Million |
| 2018 | -118.38% | 0.00% | 0.00x | 1.11x | $-7.41 Million |
| 2019 | -80.71% | 0.00% | 0.00x | 1.15x | $-4.57 Million |
| 2020 | -75.20% | 0.00% | 0.00x | 1.21x | $-4.34 Million |
| 2021 | -53.17% | 0.00% | 0.00x | 1.11x | $-4.22 Million |
| 2022 | -4.71% | 0.00% | 0.00x | 1.01x | $-13.23 Million |
| 2023 | -5.94% | 0.00% | 0.00x | 1.01x | $-11.59 Million |
| 2024 | 0.84% | 0.00% | 0.00x | 1.52x | $-3.62 Million |
| 2025 | 59.08% | 0.00% | 0.00x | 1.06x | $25.47 Million |
| 2026 | -58.34% | 0.00% | 0.00x | 1.40x | $-22.75 Million |
Industry Comparison
This section compares PharmaCyte Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaCyte Biotech Inc (PMCB) | $34.98 Million | 0.00% | 0.34x | $3.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also devel… Read more